Literature DB >> 17700271

Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.

Elif Doyuk Kartal1, Saygn Nayman Alpat, Ilhan Ozgunes, Gaye Usluer.   

Abstract

Combined treatment with pegylated interferon (PEG-IFN) and ribavirin is currently recommended for the treatment of chronic hepatitis C virus (HCV) infection. Many side effects including hair disorders have, however, been reported related to this treatment. Alopecia universalis is a severe form of hair disorder. Three cases of alopecia universalis during PEG-IFN and ribavirin combination therapy have been reported in the literature. Herein is reported a case of reversible alopecia universalis, with complete hair loss extending to the whole body, secondary to PEG-IFN alpha-2b and ribavirin combination therapy for chronic HCV infection. Hair regrowth began within 3 months of the completion of combined therapy. In case the liver disease is advanced, and virologic response occurs, treatment can still be completed, as it appears that these side effects are reversible.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700271     DOI: 10.1097/MEG.0b013e32818b27e5

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Onychomycosis Case Developing during Interferon Treatment.

Authors:  Nazan Tuna; Mustafa Teoman Erdem; Oğuz Karabay
Journal:  Balkan Med J       Date:  2013-03       Impact factor: 2.021

Review 2.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

Review 3.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

4.  Alopecia universalis in a patient with rheumatoid arthritis developed during treatment with adalimumab.

Authors:  P Ostojic; S Pavlov-Dolijanovic
Journal:  Z Rheumatol       Date:  2018-06       Impact factor: 1.372

Review 5.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

6.  Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy.

Authors:  Kamuran Turker; Betul Tas; Murat Ozkaya; Ebru Tas; Aysel Caglar; Umit Seza Tetikkurt
Journal:  Hepat Mon       Date:  2015-03-20       Impact factor: 0.660

Review 7.  Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy.

Authors:  Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2016-08-10

8.  NLRP3 inflammasome activation contributes to development of alopecia areata in C3H/HeJ mice.

Authors:  Kei Hashimoto; Yoshihito Yamada; Kota Sekiguchi; Sachi Mori; Tatsumi Matsumoto
Journal:  Exp Dermatol       Date:  2021-07-26       Impact factor: 4.511

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.